📝 Updated data from the KOMET-007 trial, presented by Harry Erba at #EHA2025, show that ziftomenib with intensive induction therapy was well tolerated in patients with newly diagnosed NPM1m or KMT2Ar AML. More news: aml-hub.com #AMLsm #leusm #MedNews #MedEd

Excellently written Nature Medicine review, and honestly the best graphics re: CAR-T toxicities (inc. infections & SPMs) that I’ve ever seen 👏 these will be used in slide decks everywhere! Congrats Kai Rejeski Joshua Hill, MD Michael Jain and thanks for writing this! #MMsm #lymsm

📣READ THE MAIN SCIENTIFIC TOPICS OF #ESHCLL2026! 4th Translational Research Conference on Chronic Lymphocytic Leukaemia March 5–7, 2026 / Stockholm, Sweden Chairs : Jennifer Brown Paolo Ghia, Michael Hallek More information ➡️bit.ly/4cfagyf #ESHCONFERENCES #CLLsm #Lmsm

Treatment Algorithm series: Diffuse Large B-Cell Lymphoma DLBCL w/ John P. Leonard, MD ✅ Work-up & 1L Rx ✅ CAR-T ✅ R/R: BiTEs/More chemo Full discussion: - oncbrothers.com/dlbcl-algo-2025 - Also on the “Oncology Brothers” podcast #HemeTwitter #OncTwitter #lymsm OncUpdates

As per Grok 4: 1) Michael Saylor 2) Jack Dorsey 3) Nayib Bukele

Why do many regulatory oncology phase III trials not accrue sufficient US patients? This issue came up repeatedly at today’s ODAC for belantamab for myeloma. And I can address it at least for myeloma. 1) In our healthcare system, opening a trial in a timely manner is a

A daily close above that orange line at the all-time high could be the ignition point for $XRP to soar to new heights! 🚀 Are you ready for the lift-off? 👀 #XRPCommunity

We are now in price discovery for $XRP #XRPCommunity

Compared with the general Swedish population, individuals with CLL had increased risks for severe COVID-19 also after Omicron emerged. ow.ly/RXeq50Wn9XW #lymphoidneoplasia

🚨Giving away a BIG #xSPECTARverse land plot NFT & a "YOU ARE $ATM" NFT to celebrate $XRP ATH 🚨 🧬Repost 🧬Follow #xSPECTAR, DS 🪝🧬🟧🟦🍌🦍🧪 & AllTheMoney 🏧 🏆 1 winner ⏱️ 72h LFG 🚀

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients | Blood Cancer Journal nature.com/articles/s4140…

Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection | Blood Cancer Journal ⁦Mayo Clinic Comprehensive Cancer Center⁩ nature.com/articles/s4140…

ASCT could still be considered in patients with primary refractory or early relapse in centers with limited access to CAR-T therapy. ow.ly/Qqqx50Wnby5 #lymphoidneoplasia #transplantation

Approach to newly diagnosed myeloma has become streamlined. Bookmark.

MDS-EB1 and -EB2 share biological characteristics and have equally poor survival, regardless of allelic status, supporting their integration. ow.ly/I29U50WnbTv #myeloidneoplasia

Bispecifics in R/R LBCL Blood Journals Portfolio: - 245 pts, 64% epcor, 60% prior CAR - mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi - mOS 7.8 mos overall (in MV model, glofi = better OS) - worse PFS/OS if trial ineligible & w/i 90 d of CAR Outcomes not great. #lymsm ashpublications.org/blood/article/…

Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection [Jun 3, 2025] Albert Suheil Atallah-Yunes et al. Witzig Blood Cancer Journal nature.com/articles/s4140… #lymsm MayoLymphoma

When BTC.D consistently closes with consecutive candles below the weekly 55 EMA (red line), I view this as a potential indicator that we might be entering an alt season…

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome ow.ly/HVvV50WtvNb #clinicaltrialsandobservations #lymphoidneoplasia